Salveen Richter analyst GOLDMAN SACHS

Currently out of the existing stock ratings of Salveen Richter, 96 are a HOLD (34.53%), 164 are a BUY (58.99%), 18 are a SELL (6.47%).

Salveen Richter

Work Performance Price Targets & Ratings Chart

Analyst Salveen Richter, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 64.83% that have a potential upside of 34.32% achieved within 269 days.

Salveen Richter’s has documented 557 price targets and ratings displayed on 49 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on APLS, Apellis Pharmaceuticals at 06-Nov-2024.

Wall Street Analyst Salveen Richter

Analyst best performing recommendations are on KRTX (KARUNA THERAPEUTICS).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS) at 11/18/2019. The price target of $109 was fulfilled within 1 day with a profit of $13 (13.54%) receiving and performance score of 135.42.

Average potential price target upside

ACAD ACADIA Pharmaceuticals ACOR Acorda Therapeutics ADPT Adaptive Biotechnologies Corp AGIO Agios Pharm ALLO Allogene Therapeutics ALNY Alnylam Pharmaceuticals BLUE Bluebird bio BMRN Biomarin Pharmaceutical BPMC Blueprint Medicines Corp CRSP Crispr Therapeutics AG DNLI Denali Therapeutics DTIL Precision BioSciences GWPH GW Pharmaceuticals plc ICPT Intercept Pharmaceuticals INCY yte KRTX Karuna Therapeutics MDGL Madrigal Pharmaceuticals MRNA Moderna MRTX Mirati Ther NTLA Intellia Therapeutics RETA Reata Pharmaceuticals SAGE Sage Therapeutic SANA Sana Biotechnology SGEN Seagen SRPT Sarepta Therapeutics TSHA Taysha Gene Therapies  VRTX Vertex Pharmaceuticals ARWR Arrowhead Pharmaceuticals ATRA Atara Biotherapeutics BIIB Biogen CNTA Centessa Pharmaceuticals PLC ADR PASG Passage Bio REGN Regeneron Pharmaceuticals RXRX Recursion Pharmaceuticals GILD Gilead Sciences RDUS Schnitzer Steel Industries AMGN Amgen QURE Uniqure NV TSVT 2Seventy Bio ADSK Autodesk FOLD Amicus Therapeutics IONS Ionis Pharmaceuticals LYEL Lyell Immunopharma ONCE Spark Therapeutics RARE Ultragenyx RCUS Arcus Biosciences SLDB Solid Biosciences LLC APLS Apellis Pharmaceuticals FDMT 4D Molecular Therapeutics 

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$27

$10.58 (64.43%)

$27

13 days ago
(07-Nov-2024)

8/22 (36.36%)

$9.79 (56.89%)

119

Buy

$28

$11.58 (70.52%)

$28

13 days ago
(07-Nov-2024)

0/4 (0%)

$10.79 (62.70%)

Hold

1 months 10 days ago
(10-Oct-2024)

11/14 (78.57%)

$9.98 (39.89%)

141

Buy

$23

$6.58 (40.07%)

$30

3 months 12 days ago
(08-Aug-2024)

0/3 (0%)

$7.28 (46.31%)

Buy

$20

$3.58 (21.80%)

$28

3 months 13 days ago
(07-Aug-2024)

16/21 (76.19%)

$4.83 (31.84%)

184

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Salveen Richter is most bullish on?

Potential upside of $126.74 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is Salveen Richter is most reserved on?

Potential downside of -$5.87 has been obtained for INCY (YTE)

What Year was the first public recommendation made by Salveen Richter?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?